Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin

Antioxidants and Redox Signaling

Volumn 22, Issue 2, 2015, Pages 121-134

  Aleyasin, Hossein ^a,b   Karuppagounder, Saravanan S ^a,b   Kumar, Amit ^a,b   Sleiman, Sama ^a,b   Basso, Manuela ^a,b   Ma, Thong ^a,b   Siddiq, Ambreena ^a,b   Chinta, Shankar J ^c   Brochier, Camille ^a,b   Langley, Brett ^a,b   Haskew Layton, Renee ^a,b   Bane, Susan L ^d   Riggins, Gregory J ^e   Gazaryan, Irina ^a,b   Starkov, Anatoly A ^b   Andersen, Julie K ^c   Ratan, Rajiv R ^a,b  

^a Burke Cornell Medical Research Institute   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d BINGHAMTON UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BIOCHANIN A; CICLOPIROXOLAMINE; CLINDAMYCIN; CLOFOCTOL; DAIDZEIN; FENBENDAZOLE; HYDRALAZINE; HYDROXYUREA; HYDROXYZINE EMBONATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IBUPROFEN; INDOPROFEN; ISOFLAVONE; MEBENDAZOLE; MONENSIN; NABUMETONE; NAFCILLIN; PRAMOCAINE; REACTIVE OXYGEN METABOLITE; SULFACHLORPYRIDAZINE; TILORONE; TRIMETHOPRIM; TRIPELENNAMINE; TROPICAMIDE; TUBULIN; UNINDEXED DRUG; ZOMEPIRAC; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ADULT; ANIMAL CELL; ARTICLE; BRAIN CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; EMBRYO; GENETIC TRANSCRIPTION; LIVER MITOCHONDRION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL NECROSIS; NEUROBLAST; NONHUMAN; OXIDATIVE STRESS; PHARMACOPHORE; PROTEIN EXPRESSION; PROTEIN STABILITY; ANIMAL; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; WESTERN BLOTTING;

ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HIPPOCAMPUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MEBENDAZOLE; MICE; NEURONS; TUBULIN;

EID: 84920127063     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5595     Document Type: Article

References (61)

1. Aminova LR, Chavez JC, Lee J, Ryu H, Kung A, Lamanna JC, and Ratan RR. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem 280: 3996-4003, 2005.
2. Amir S, Wang R, Simons JW, and Mabjeesh NJ. SEPT9-v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation. J Biol Chem 284: 11142-11151, 2009.
3. Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, and Swanson RA. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 9: 119-126, 2006.
4. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, and Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451: 1008-1012, 2008.
5. Bai RY, Staedtke V, Aprhys CM, Gallia GL, and Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol 13: 974-982, 2011.
6. Bailey MJ, Worrall S, de Jersey J, and Dickinson RG. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem Biol Interact 115: 153-166, 1998.
7. Bounoutas A, Kratz J, Emtage L, Ma C, Nguyen KC, and Chalfie M. Microtubule depolymerization in Caenor-habditis elegans touch receptor neurons reduces gene expression through a p38 MAPK pathway. Proc Natl Acad Sci USA 108: 3982-3987, 2011.
8. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
9. Dhar SK, Xu Y, and St Clair DK. Nuclear factor kappaB-and specificity protein 1-dependent p53-mediated bi-directional regulation of the human manganese superoxide dismutase gene. J Biol Chem 285: 9835-9846, 2010.
10. Domingo A, Al-Yahya AA, Asiri Y, Eng JJ, Lam T, and Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury. J Neurotrauma 29: 865-879, 2012.
11. Elewa HF, Kozak A, Johnson MH, Ergul A, and Fagan SC. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens 25: 855-859, 2007.
12. Friedman PA and Platzer EG. Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 544: 605-614, 1978.
13. Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, Va-liente R, and Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 28: 675-685, 2008.
14. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, and Ferriero DM. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci 31: 403-411, 2009.
15. Haskew-Layton RE, Payappilly JB, Smirnova NA, Ma TC, Chan KK, Murphy TH, Guo H, Langley B, Sultana R, Butterfield DA, Santagata S, Alldred MJ, Gazaryan IG, Bell GW, Ginsberg SD, and Ratan RR. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci USA 107: 17385-17390, 2010.
16. Hastie SB, Williams RC, Jr., Puett D, and Macdonald TL. The binding of isocolchicine to tubulin. Mechanisms of ligand association with tubulin. J Biol Chem 264: 6682-6688, 1989.
17. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, and Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8: 143-153, 2005.
18. Jin KL, Mao XO, and Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97: 10242-10247, 2000.
19. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L. Mi-crotubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem 278: 7445-7452, 2003.
20. Jung-Cook H. Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis. Expert Rev Clin Pharmacol 5: 21-30, 2012.
21. Kaelin WG, Jr. and Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
22. Kamal A, Kashi Reddy M, Shaik TB, Rajender, Srikanth YV, Santhosh Reddy V, Bharath Kumar G, and Kalivendi SV. Synthesis of terphenyl benzimidazoles as tubulin polymerization inhibitors. Eur J Med Chem 50: 9-17, 2012.
23. Knowles HJ, Tian YM, Mole DR, and Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 95: 162-169, 2004.
24. Kwa MS, Veenstra JG, Van Dijk M, and Roos MH. Beta-tubulin genes from the parasitic nematode Haemonchus contortus modulate drug resistance in Caenorhabditis ele-gans. J Mol Biol 246: 500-510, 1995.
25. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 18: 885-936, 1988.
26. Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, and Ratan RR. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 28: 163-176, 2008.
27. Li D, Bai T, and Brorson JR. Adaptation to moderate hypoxia protects cortical neurons against ischemia-reperfusion injury and excitotoxicity independently of HIF-1alpha. Exp Neurol 230: 302-310, 2011.
28. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, and Wenger RH. The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angio-genesis. FASEB J 17: 761-763, 2003.
29. Lubega GW and Prichard RK. Specific interaction of benzimidazole anthelmintics with tubulin: high-affinity binding and benzimidazole resistance in Haemonchus contortus. Mol Biochem Parasitol 38: 221-232, 1990.
30. Ma C and D'Mello SR. Neuroprotection by histone dea-cetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J Biol Chem 286: 4819-4828, 2011.
31. Majmundar AJ, Wong WJ, and Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309, 2010.
32. McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, and Ratan RR. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Hun-tington disease. EMBO Mol Med 2: 349-370, 2010.
33. McCracken RO and Stillwell WH. A possible biochemical mode of action for benzimidazole anthelmintics. Int J Parasitol 21: 99-104, 1991.
34. Moriya M and Linder MC. Vesicular transport and apo-transferrin in intestinal iron absorption, as shown in the Caco-2 cell model. Am J Physiol Gastrointest Liver Physiol 290: G301-G309, 2006.
35. Mu D, Chang YS, Vexler ZS, and Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 195: 407-415, 2005.
36. Murphy TH and Baraban JM. Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents. Brain Res Dev Brain Res 57: 146-150, 1990.
37. Nagel S, Papadakis M, Chen R, Hoyte LC, Brooks KJ, Gallichan D, Sibson NR, Pugh C, and Buchan AM. Neu-roprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 31: 132-143, 2011.
38. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, and Schofield CJ. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481-501, 2010.
39. Nechipurenko IV and Broihier HT. FoxO limits microtu-bule stability and is itself negatively regulated by micro-tubule disruption. J Cell Biol 196: 345-362, 2012.
40. Niatsetskaya Z, Basso M, Speer RE, McConoughey SJ, Coppola G, Ma TC, and Ratan RR. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 12: 435-443, 2010.
41. Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, and Meisel A. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34: 1981-1986, 2003.
42. Prichard RK. Mode of action of the anthelminthic thia-bendazole in Haemonchus contortus. Nature 228: 684-685, 1970.
43. Ratan RR, Murphy TH, and Baraban JM. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci 14: 4385-4392, 1994.
44. Ratan RR, Siddiq A, Aminova L, Lange PS, Langley B, Ayoub I, Gensert J, and Chavez J. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 35: 2687-2689, 2004.
45. Ratan RR, Siddiq A, Aminova L, Langley B, McCo-noughey S, Karpisheva K, Lee HH, Carmichael T, Korn-blum H, Coppola G, Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, and Gazaryan I. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad Sci 1147: 383-394, 2008.
46. Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S, Sen CK, Gazaryan I, Cho S, Fink M, and LaManna J. Harnessing hypoxic adaptation to prevent, treat, and repair stroke. J Mol Med (Berl) 85: 1331-1338, 2007.
47. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW, Depinho RA, and Kaelin WG, Jr. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 103: 105-110, 2006.
48. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85, 2005.
49. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, and Ratan RR. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREB-independent pathways. J Neurosci 29: 8828-8838, 2009.
50. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, and Ratan RR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743, 2005.
51. Sims NR. Rapid isolation of metabolically active mitochondria from rat brain and subregions using Percoll density gradient centrifugation. J Neurochem 55: 698-707, 1990.
52. Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, and Ratan RR. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 31: 6858-6870, 2011.
53. Smirnova NA, Rakhman I, Moroz N, Basso M, Payappilly J, Kazakov S, Hernandez-Guzman F, Gaisina IN, Kozi-kowski AP, Ratan RR, and Gazaryan IG. Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem Biol 17: 380-391, 2010.
54. Starkov AA. Measurement of mitochondrial ROS production. Methods Mol Biol 648: 245-255, 2010.
55. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, and Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 24: 7779-7788, 2004.
56. Taylor CT and McElwain JC. Ancient atmospheres and the evolution of oxygen sensing via the hypoxia-inducible factor in metazoans. Physiology (Bethesda) 25: 272-279, 2010.
57. Vinaud MC, Ferreira CS, Lino Junior Rde S, and Bezerra JC. Taenia crassiceps: energetic and respiratory metabolism from cysticerci exposed to praziquantel and albendazole in vitro. Exp Parasitol 120: 221-226, 2008.
58. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, and Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Bio-technol 26: 343-351, 2008.
59. Wang GL and Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237, 1995.
60. Wang X, Miller DS, and Zheng W. Intracellular localization and subsequent redistribution of metal transporters in a rat choroid plexus model following exposure to manganese or iron. Toxicol Appl Pharmacol 230: 167-174, 2008.
61. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, and Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19: 9821-9830, 1999.